BL B16D1
Alternative Names: BL-B16D1Latest Information Update: 02 Oct 2024
At a glance
- Originator Sichuan Baili Pharmaceutical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Breast cancer; Solid tumours
Most Recent Events
- 02 Oct 2024 Phase-I clinical trials in Solid tumour (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (NCT06493864)
- 26 Aug 2024 Phase-I clinical trials in Breast cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV) (NCT06493864)
- 18 Jul 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (NCT06475131)